24/7 Market News Snapshot 16 September, 2025 – Enveric Biosciences, Inc. Common Stock (NASDAQ:ENVB)

September 16, 2025

DENVER, Colo., 16 September, 2025 (www.247marketnews.com) – (NASDAQ:ENVB) are discussed in this article.
Enveric Biosciences, Inc. is demonstrating a positive trend in the pre-market, trading at $0.956, reflecting a 1.67% increase from the previous day’s close of $0.940, alongside a robust trading volume of 1.98 million shares. This upward momentum, indicative of strong market interest, may signal positive investor sentiment driven by recent advancements within the biopharmaceutical sector.

In a major development for the company, Enveric has received a written response from the U.S. Food and Drug Administration (FDA) regarding its request for a Pre-Investigational New Drug (pre-IND) meeting for its lead program, EB-003. The FDA has encouraged the company to proceed directly with submitting its Investigational New Drug (IND) application, a move that highlights Enveric’s progress toward clinical development.

Dr. Joseph Tucker, the Chief Executive Officer of Enveric Biosciences, expressed optimism regarding this endorsement from the FDA, viewing it as a validation of the company’s strategic direction. He stated, “The IND submission for EB-003 marks a pivotal moment for Enveric. We are eager to execute our clinical strategy effectively and enhance value across our development pipeline.”

EB-003 is designed as a dual-acting compound targeting depression and anxiety, characterized by its innovative mechanism that fosters stable neuroplastic changes while avoiding hallucinogenic side effects commonly linked with alternative treatments. Enveric’s strong patent position, which includes 26 issued U.S. patents and 60 pending applications globally, reinforces its leadership within this burgeoning therapeutic landscape.

As Enveric progresses toward its IND submission for EB-003, the company remains dedicated to addressing unmet medical needs in psychiatric and neurological disorders through the development of next-generation small-molecule therapeutics focused on patient outcomes.

Related news for (ENVB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.